{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:15:28Z","timestamp":1790615728164,"version":"4.1.0"},"reference-count":64,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-\u03b1)-inhibitors and an IL12\/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90\/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90\/75 were lower in this real-world study.<\/jats:p>","DOI":"10.2340\/actadv.v102.206","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:26:14Z","timestamp":1648725974000},"page":"adv00712","source":"Crossref","is-referenced-by-count":30,"title":["Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort"],"prefix":"10.2340","volume":"102","author":[{"given":"Marloes E.","family":"Van Muijen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.M.","family":"Groenewoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol E.","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcellus D.","family":"Njoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.P.","family":"Dodemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else N.","family":"Kop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje A.M.","family":"Berends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein I.A.","family":"Koetsier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Mommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.M.","family":"K\u00f6rver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.","family":"Tupker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"De Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizelotte J.M.T.","family":"Weppner-Parren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes M.","family":"Kleinpenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid L.A.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Peter","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula P.M.","family":"Van L\u00fcmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juul M.P.A.","family":"Van den Reek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke  M.G.J.","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"18630","doi-asserted-by":"crossref","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res 2019; 2019: 2546161.","DOI":"10.1155\/2019\/2546161"},{"key":"18631","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2019\/2546161","DOI":"10.1155\/2019\/2546161"},{"key":"18632","doi-asserted-by":"crossref","unstructured":"Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mohd Mustapa MF, Samarasekera E, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137: 1646-1654.","DOI":"10.1016\/j.jid.2017.04.009"},{"key":"18633","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2017.04.009","DOI":"10.1016\/j.jid.2017.04.009"},{"key":"18634","doi-asserted-by":"crossref","unstructured":"Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol 2018; 79: 135-144.e7.","DOI":"10.1016\/j.jaad.2018.02.027"},{"key":"18635","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.02.027","DOI":"10.1016\/j.jaad.2018.02.027"},{"key":"18636","doi-asserted-by":"crossref","unstructured":"Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE 2019; 14: e0220868.","DOI":"10.1371\/journal.pone.0220868"},{"key":"18637","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0220868","DOI":"10.1371\/journal.pone.0220868"},{"key":"18638","doi-asserted-by":"crossref","unstructured":"Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daud\u00e9n E, S\u00e1nchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"18639","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archdermatol.2011.2768","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"18640","doi-asserted-by":"crossref","unstructured":"Zweegers J, Groenewoud JMM, van den Reek J, Otero ME, van de Kerkhof PCM, Driessen RJB, et al. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol 2017; 176: 1001-1009.","DOI":"10.1111\/bjd.15023"},{"key":"18641","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15023","DOI":"10.1111\/bjd.15023"},{"key":"18642","doi-asserted-by":"crossref","unstructured":"Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol 2016; 74: 851-861.e4.","DOI":"10.1016\/j.jaad.2015.12.017"},{"key":"18643","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2015.12.017","DOI":"10.1016\/j.jaad.2015.12.017"},{"key":"18644","doi-asserted-by":"crossref","unstructured":"Carrera CG, Dapavo P, Malagoli P, Naldi L, Arancio L, Gaiani F, et al. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. J Dermatolog Treat 2018; 29: 481-486.","DOI":"10.1080\/09546634.2017.1395805"},{"key":"18645","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2017.1395805","DOI":"10.1080\/09546634.2017.1395805"},{"key":"18646","doi-asserted-by":"crossref","unstructured":"Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Dermatol Sci 2020; 99: 53-61.","DOI":"10.1016\/j.jdermsci.2020.06.003"},{"key":"18647","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.06.003","DOI":"10.1016\/j.jdermsci.2020.06.003"},{"key":"18648","doi-asserted-by":"crossref","unstructured":"Cinelli E, Fabbrocini G, Megna M. Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation. Int J Dermatol 2022; 61: e107-e108.","DOI":"10.1111\/ijd.15644"},{"key":"18649","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.15644","DOI":"10.1111\/ijd.15644"},{"key":"18650","doi-asserted-by":"crossref","unstructured":"West BT. Analyzing longitudinal data with the linear mixed models procedure in SPSS. Eval Health Prof 2009; 32: 207-228.","DOI":"10.1177\/0163278709338554"},{"key":"18651","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/0163278709338554","DOI":"10.1177\/0163278709338554"},{"key":"18652","doi-asserted-by":"crossref","unstructured":"van L\u00fcmig PPM, Driessen RJB, Kievit W, Boezeman JBM, van de Kerkhof PCM, de Jong EMGJ. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol 2013; 68: 57-63.","DOI":"10.1016\/j.jaad.2012.05.040"},{"key":"18653","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2012.05.040","DOI":"10.1016\/j.jaad.2012.05.040"},{"key":"18654","doi-asserted-by":"crossref","unstructured":"Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: Cd011535.","DOI":"10.1002\/14651858.CD011535.pub3"},{"key":"18655","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD011535.pub3","DOI":"10.1002\/14651858.CD011535.pub3"},{"key":"18656","doi-asserted-by":"crossref","unstructured":"Xu S, Gao X, Deng J, Yang J, Pan F. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. J Dtsch Dermatol Ges 2021; 19: 47-56.","DOI":"10.1111\/ddg.14308"},{"key":"18657","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14308","DOI":"10.1111\/ddg.14308"},{"key":"18658","doi-asserted-by":"crossref","unstructured":"Ohata C, Ohyama B, Katayama E, Nakama T. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol 2020; 47: 405-408.","DOI":"10.1111\/1346-8138.15247"},{"key":"18659","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.15247","DOI":"10.1111\/1346-8138.15247"},{"key":"18660","doi-asserted-by":"crossref","unstructured":"Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, et al. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges 2017; 15: 309-317.","DOI":"10.1111\/ddg.13191"},{"key":"18661","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.13191","DOI":"10.1111\/ddg.13191"},{"key":"18662","doi-asserted-by":"crossref","unstructured":"Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol 2021; 157: 66-73.","DOI":"10.1001\/jamadermatol.2020.4202"},{"key":"18663","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.4202","DOI":"10.1001\/jamadermatol.2020.4202"},{"key":"18664","doi-asserted-by":"crossref","unstructured":"Herrera-Acosta E, Garriga-Martina GG, Su\u00e1rez-P\u00e9rez JA, Mart\u00ednez-Garc\u00eda EA, Herrera-Ceballos E. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: real-world practice. Dermatol Ther 2020; 33: e13313.","DOI":"10.1111\/dth.13313"},{"key":"18665","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13313","DOI":"10.1111\/dth.13313"},{"key":"18666","doi-asserted-by":"crossref","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol 2021; 85: 1028-1030.","DOI":"10.1016\/j.jaad.2021.01.025"},{"key":"18667","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2021.01.025","DOI":"10.1016\/j.jaad.2021.01.025"},{"key":"18668","doi-asserted-by":"crossref","unstructured":"Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat 2020; 31: 476-483.","DOI":"10.1080\/09546634.2019.1671577"},{"key":"18669","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2019.1671577","DOI":"10.1080\/09546634.2019.1671577"},{"key":"18670","doi-asserted-by":"crossref","unstructured":"Galluzzo M, Caldarola G, De Simone C, Bernardini N, Moretta G, Pallotta S, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther 2021; 21: 1299-1310.","DOI":"10.1080\/14712598.2021.1941862"},{"key":"18671","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14712598.2021.1941862","DOI":"10.1080\/14712598.2021.1941862"},{"key":"18672","doi-asserted-by":"crossref","unstructured":"Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol 2019; 33: 553-559.","DOI":"10.1111\/jdv.15288"},{"key":"18673","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15288","DOI":"10.1111\/jdv.15288"},{"key":"18674","doi-asserted-by":"crossref","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology 2021 Nov 12 [Epub ahead of print].","DOI":"10.1159\/000519924"},{"key":"18675","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000519924","DOI":"10.1159\/000519924"},{"key":"18676","doi-asserted-by":"crossref","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and\/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther 2021; 34: e14673.","DOI":"10.1111\/dth.14673"},{"key":"18677","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14673","DOI":"10.1111\/dth.14673"},{"key":"18678","doi-asserted-by":"crossref","unstructured":"Rivera R, Velasco M, Vidal D, Carrascosa JM, Daud\u00e9n E, Vilarrasa E, et al. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: a Spanish multicentre retrospective study. Dermatol Ther 2020; 33: e14066.","DOI":"10.1111\/dth.14066"},{"key":"18679","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14066","DOI":"10.1111\/dth.14066"},{"key":"18680","doi-asserted-by":"crossref","unstructured":"Schwarz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, Ajgeiy KK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol 2021; 101: adv00579.","DOI":"10.2340\/actadv.v101.351"},{"key":"18681","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v101.351","DOI":"10.2340\/actadv.v101.351"},{"key":"18682","doi-asserted-by":"crossref","unstructured":"Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.","DOI":"10.1111\/bjd.16102"},{"key":"18683","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16102","DOI":"10.1111\/bjd.16102"},{"key":"18684","doi-asserted-by":"crossref","unstructured":"Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther 2022; 35: e15166.","DOI":"10.1111\/dth.15166"},{"key":"18685","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15166","DOI":"10.1111\/dth.15166"},{"key":"18686","doi-asserted-by":"crossref","unstructured":"Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158-1166.","DOI":"10.1111\/bjd.18333"},{"key":"18687","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18333","DOI":"10.1111\/bjd.18333"},{"key":"18688","doi-asserted-by":"crossref","unstructured":"Kem\u00e9ny L, Berggren L, Dossenbach M, Dutronc Y, Paul C. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. J Dermatolog Treat 2019; 30: 19-26.","DOI":"10.1080\/09546634.2018.1473551"},{"key":"18689","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2018.1473551","DOI":"10.1080\/09546634.2018.1473551"},{"key":"18690","doi-asserted-by":"crossref","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, Toth D, Messina I, You R, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol 2017; 177: 1033-1042.","DOI":"10.1111\/bjd.15706"},{"key":"18691","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15706","DOI":"10.1111\/bjd.15706"},{"key":"18692","doi-asserted-by":"crossref","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol 2019; 80: 70-79.e3.","DOI":"10.1016\/j.jaad.2018.06.039"},{"key":"18693","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.039","DOI":"10.1016\/j.jaad.2018.06.039"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/206\/4190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/206\/4191","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/206\/4190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:18:26Z","timestamp":1655918306000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":64,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.206","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}